Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and Soleno Therapeutics, Inc.

Biotech Giants' SG&A Expenses: A Decade of Change

__timestampCytokinetics, IncorporatedSoleno Therapeutics, Inc.
Wednesday, January 1, 2014172680002917513
Thursday, January 1, 2015196670007878291
Friday, January 1, 2016278230008366794
Sunday, January 1, 2017364680006610381
Monday, January 1, 2018312820006556000
Tuesday, January 1, 2019396100006930000
Wednesday, January 1, 2020528200008758000
Friday, January 1, 20219680300010806000
Saturday, January 1, 20221779770009844000
Sunday, January 1, 202317361200013481000
Loading chart...

Unlocking the unknown

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Cytokinetics, Incorporated and Soleno Therapeutics, Inc. from 2014 to 2023. Cytokinetics, a leader in muscle biology, has seen its SG&A expenses grow by over 900% during this period, peaking in 2022. This reflects their aggressive expansion and investment in research and development. In contrast, Soleno Therapeutics, focusing on rare diseases, maintained a more stable SG&A trajectory, with a modest increase of around 360%. This stability suggests a more conservative growth strategy. The data highlights the contrasting approaches of these two companies in managing operational costs, providing valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025